{'fraction_non_alphanumeric': 0.02457002457002457, 'fraction_numerical': 0.03562653562653563, 'mean_word_length': 5.3671875, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Amyloid‐like deposits in the brain of transgenic mice overexpressing S100B protein

S100 calcium‐binding protein B (S100B) is a member of the S100 family, mainly expressed and secreted by astrocytes in the Central Nervous System. Extracellular levels of this protein have been used as a general marker of brain injury, particularly in blood serum and cerebrospinal fluid (CSF). Mice overexpressing S100B (S100BTg) was firstly developed to better understand the Down Syndrome and Alzheimer's Disease, once both S100B and amyloid precursor protein (APP) genes are located in chromosome 21. Also, it was previously demonstrated the exacerbation of amyloidogenesis in transgenic mice for both human APP and S100B, but the influence of this protein on APP processing had not yet been investigated in the S100BTg itself.